These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17609485)

  • 1. Timing of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Naina HV; Harris S; Singla A
    JAMA; 2007 Jul; 298(1):37; author reply 37-8. PubMed ID: 17609485
    [No Abstract]   [Full Text] [Related]  

  • 2. Routine vs selective invasive strategies in acute coronary syndromes.
    Bavry AA; Kumbhani DJ
    JAMA; 2005 Dec; 294(22):2844-5; author reply 2845-6. PubMed ID: 16352787
    [No Abstract]   [Full Text] [Related]  

  • 3. Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction.
    Cannon CP
    Coron Artery Dis; 1999 Dec; 10(8):561-6. PubMed ID: 10599534
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
    JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute coronary syndrome: new advances and nursing strategies.
    Palatnik AM
    Dimens Crit Care Nurs; 2000; 19(5):22-6. PubMed ID: 11998062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions.
    Mahaffey KW; Harrington RA
    JAMA; 2007 Feb; 297(6):636-9. PubMed ID: 17299199
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
    Campbell P
    N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
    [No Abstract]   [Full Text] [Related]  

  • 9. 'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes.
    Antman EM
    Eur Heart J; 2002 Sep; 23(18):1408-11. PubMed ID: 12208217
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.
    Antman EM
    Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing unstable angina in high-risk patients.
    Chew DP; Moliterno DJ
    J Invasive Cardiol; 2002 Feb; 14 Suppl A():31A-48A. PubMed ID: 11847404
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acute coronary ischemic syndrome without ST elevation. Role of glycoprotein IIB/IIIA inhibitors and percutaneous coronary interventions].
    Peña Duque MA
    Arch Cardiol Mex; 2006; 76 Suppl 2():S249-51. PubMed ID: 17017111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drawbacks of nonrandomized trials in acute coronary syndromes.
    Biondi-Zoccai GG; Abbate A; Agostoni P; Valgimigli M; Sangiorgi GM
    Am J Cardiol; 2006 Jan; 97(1):151. PubMed ID: 16377303
    [No Abstract]   [Full Text] [Related]  

  • 15. Fast, aggressive treatment for myocardial infarction urged.
    Mitka M
    JAMA; 2000 Dec; 284(23):2985-6. PubMed ID: 11122567
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence.
    Singh S; Gopal AK; Bahl VK
    Indian Heart J; 2005; 57(3):201-9. PubMed ID: 16196176
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of IIb/IIIa receptor blockade in patients with unstable angina.
    Vahanian A; Michaud P; Garbarz E
    Semin Interv Cardiol; 1999 Jun; 4(2):61-6. PubMed ID: 10473874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
    Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML
    Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proper use of glycoprotein IIb/IIIa inhibitors in patients with non-sT elevation acute coronary syndromes undergoing coronary angiography: frankly, my dear, I don't give a damn.
    Bovenzi F; De Luca L
    J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):166-8. PubMed ID: 16645380
    [No Abstract]   [Full Text] [Related]  

  • 20. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.